Whitehawk Therapeutics, Inc. (WHWK)
4.05
-0.15
(-3.57%)
USD |
NASDAQ |
Sep 21, 16:00
4.05
0.00 (0.00%)
After-Hours: 20:00
Whitehawk Therapeutics Enterprise Value : 49.46M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 49.46M |
| September 17, 2026 | 42.61M |
| September 16, 2026 | 40.33M |
| September 15, 2026 | 43.18M |
| September 14, 2026 | 42.04M |
| September 11, 2026 | 44.32M |
| September 10, 2026 | 42.04M |
| September 09, 2026 | 48.89M |
| September 08, 2026 | 60.29M |
| September 04, 2026 | 72.26M |
| September 03, 2026 | 73.97M |
| September 02, 2026 | 78.53M |
| September 01, 2026 | 73.97M |
| August 31, 2026 | 68.84M |
| August 28, 2026 | 73.40M |
| August 27, 2026 | 87.65M |
| August 26, 2026 | 85.94M |
| August 25, 2026 | 99.62M |
| August 24, 2026 | 88.22M |
| August 21, 2026 | 79.67M |
| August 20, 2026 | 85.37M |
| August 19, 2026 | 87.65M |
| August 18, 2026 | 81.38M |
| August 17, 2026 | 74.54M |
| August 14, 2026 | 64.28M |
| Date | Value |
|---|---|
| August 13, 2026 | 76.82M |
| August 12, 2026 | 78.53M |
| August 11, 2026 | 76.25M |
| August 10, 2026 | 69.41M |
| August 07, 2026 | 81.38M |
| August 06, 2026 | 77.96M |
| August 05, 2026 | 42.04M |
| August 04, 2026 | 46.04M |
| August 03, 2026 | 35.77M |
| July 31, 2026 | 29.50M |
| July 30, 2026 | 29.50M |
| July 29, 2026 | 18.67M |
| July 28, 2026 | 19.81M |
| July 27, 2026 | 20.95M |
| July 24, 2026 | 21.52M |
| July 23, 2026 | 28.36M |
| July 22, 2026 | 37.48M |
| July 21, 2026 | 32.92M |
| July 20, 2026 | 26.08M |
| July 17, 2026 | 31.78M |
| July 16, 2026 | 31.78M |
| July 15, 2026 | 29.50M |
| July 14, 2026 | 27.22M |
| July 13, 2026 | 28.93M |
| July 10, 2026 | 36.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 599.19M |
| Amgen, Inc. | 251.80B |
| Anika Therapeutics, Inc. | 265.34M |
| BioCryst Pharmaceuticals, Inc. | 2.699B |
| Imunon, Inc. | 7.326M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.64M |
| Total Expenses (Quarterly) | 16.64M |
| EPS Diluted (Quarterly) | -0.2008 |
| Earnings Yield | -27.50% |
| Normalized Earnings Yield | -27.50 |